# Richard Görlick

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-gorlick/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,489 |
| Field | Sarcoma Diagnosis and Treatment |
| h-index | 90 |
| i10-index | 299 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5032743242 |
| ORCID iD | https://orcid.org/0000-0001-8995-2929 |
| Works | 786 |

## Researcher papers

Showing 12 of 14.

- [Advancing therapy for osteosarcoma](https://scholariq.org/papers/advancing-therapy-for-osteosarcoma/)
- [Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort](https://scholariq.org/papers/survival-and-prognosis-with-osteosarcoma-outcomes-in-more-than-2000-patients-in/)
- [The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis](https://scholariq.org/papers/the-membrane-cytoskeleton-linker-ezrin-is-necessary-for-osteosarcoma-metastasis/)
- [Current and future therapeutic approaches for osteosarcoma](https://scholariq.org/papers/current-and-future-therapeutic-approaches-for-osteosarcoma/)
- [Biology and Therapeutic Advances for Pediatric Osteosarcoma](https://scholariq.org/papers/biology-and-therapeutic-advances-for-pediatric-osteosarcoma/)
- [Osteosarcoma](https://scholariq.org/papers/osteosarcoma/)
- [Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial](https://scholariq.org/papers/comparison-of-mapie-versus-map-in-patients-with-a-poor-response-to-preoperative/)
- [Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial](https://scholariq.org/papers/methotrexate-doxorubicin-and-cisplatin-map-plus-maintenance-pegylated-interferon/)
- [EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment](https://scholariq.org/papers/euramos-1-an-international-randomised-study-for-osteosarcoma-results-from-pre/)
- [New targets and approaches in osteosarcoma](https://scholariq.org/papers/new-targets-and-approaches-in-osteosarcoma/)
- [Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma](https://scholariq.org/papers/immune-infiltration-and-pd-l1-expression-in-the-tumor-microenvironment-are/)
- [Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma](https://scholariq.org/papers/frequency-of-pathogenic-germline-variants-in-cancer-susceptibility-genes-in/)

## Researcher topics

- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Bone Tumor Diagnosis and Treatments](https://scholariq.org/topics/bone-tumor-diagnosis-and-treatments/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.